Difference between revisions of "Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5 (Q9818)"
Jump to navigation
Jump to search
(Created claim: title (P93): Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 823-829, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 823-829 | ||
| Property / Page(s): 823-829 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Riechelmann H
0 references
2008
0 references
Oral. Oncol.
0 references
44
0 references
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
0 references
823-829
0 references
